Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’
- 250 Downloads
Background Drug-related morbidity (DRM) is common and to some extent preventable, and associated with considerable costs in patients attending hospital. In outpatients and in the general public corresponding data are limited, but pharmacists’ expert opinion has suggested high rates of DRM also in US ambulatory care. It is unknown if the results are applicable in Sweden today. Objective To estimate the proportions of patients with DRM and preventable DRM and the cost-of-illness (COI) of DRM in Sweden based on pharmacists’ expert opinion. Setting Swedish healthcare. Method The study applied a conceptual model of DRM based on a decision tree. An expert panel of pharmacists determined the probabilities of therapeutic outcomes of medication therapy. The COI analysis included direct costs from the healthcare perspective. Sensitivity analyses were performed for variations in probabilities and pathway costs. Main outcome measure DRM included new medical problems (adverse drug reactions, drug dependence and intoxications) and therapeutic failures (insufficient effects of medicines and morbidity due to untreated indication). Results The expert panel estimated that 61 ± 14 % (mean ± SD) of all patients attending healthcare suffered from DRM, of which 29 ± 8 % suffered from new medical problems, 18 ± 6 % from therapeutic failures, and 15 ± 7 % from a combination of both. The DRM was considered preventable in 45 ± 15 % of the patients with DRM. The estimated COI was EUR 997 per patient attending healthcare, corresponding to an annual cost of EUR 6,600 million to the Swedish healthcare system. The COI ranged from EUR 490 to EUR 1,314 when varying the participants’ probabilities of DRM and clinical outcomes from the first to the third quartile. Of the pathway costs, the COI was most sensitive to variation in the cost of prolonged hospital stay (COI range EUR 953–1,306). Conclusion According to pharmacists’ expert opinion, a large proportion of patients in Sweden experience DRM and preventable DRM, and the estimated COI of DRM is extensive. Since observational studies have not addressed the burden of DRM to the general public, this study adds the pharmacists’ perception on DRM. Other healthcare professionals’ perceptions on DRM need to be investigated in future studies.
KeywordsAdverse effects Cost of illness Decision trees Delphi technique Drug-related morbidity Drug therapy Preventability Sweden
We thank all the participants, in the piloting of the decision tree and in the final study. We also like to thank Lyle Bootman and colleagues in the College of Pharmacy, University of Arizona, for appreciated contributions in the adaptation of the conceptual model.
The research is part of the DRUMS project (Drug-related morbidity and mortality in Sweden: prevalence, preventability and costs), and is funded by an unrestricted grant from The National Corporation of Swedish Pharmacies (Apoteket AB). The sponsor had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. The authors’ work was independent from the sponsor.
Conflicts of interest
The authors have no conflicts of interest to declare. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official or as reflecting the views of the Medical Products Agency.
- 1.Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566–76.PubMedCrossRefGoogle Scholar
- 10.Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192–9.Google Scholar
- 13.Nysam. Nyckeltal 2009 rapport Vårdkonsumtion. Swedish: The Association; 2010. p. 1–47.Google Scholar
- 14.Statistics Sweden. Sweden’s population nearing 9.5 million. [Updated 18 Feb 2011; cited 31 Jan 2012]. Available from: http://www.scb.se/Pages/PressRelease____308294.aspx.
- 16.Evans RS, Classen DC, Stevens LE, Pestotnik SL, Gardner RM, Lloyd JF, et al. Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care. 1993;161–5.Google Scholar
- 20.Swedish Association of Local Authorities and Regions. Statistik om hälso-och sjukvård samt regional utveckling 2010. Swedish: The Association; 2011. p. 1–216.Google Scholar
- 21.Swedish Association of Local Authorities and Regions. Jämförelse av kostnader och verksamhet på sjukhuskliniker 2009. Swedish: The Association; 2010. p. 1–38.Google Scholar
- 22.Swedish Association of Local Authorities and Regions. Löne-och prisförändring för landsting och KPI. [Updated 27 May 2009; cited 31 Jan 2012]. Available from: http://www.skl.se/vi_arbetar_med/ekonomi/budget_och_planering/prisindex/landstingsprisindex.Swedish.
- 23.Sveriges Riksbank. Årsgenomsnitt valutakurser (ackumulerat). [Updated 1 Jan 2011; cited 31 Jan 2012]. Available from: http://www.riksbank.se/sv/Rantor-och-valutakurser/Arsgenomsnitt-valutakurser/. Swedish.
- 27.Statistics Sweden. Svenska hälsoräkenskaper 2001–2010. [Updated 30 Mar 2012; cited 20 Apr 2012]. Available from: http://www.scb.se/Pages/ProductTables____231546.aspx.Swedish.
- 28.Yousuf MI. Using experts’ opinions through Delphi techniques. Pract Assess Res Eval. 2007;12(4):1–8.Google Scholar
- 29.Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. RAND Corp. 1968;P-3925:1–14.Google Scholar